Nonalcoholic fatty liver disease and HIV infection

Seminars in Liver Disease

Volumn 32, Issue 2, 2012, Pages 158-166

  Vallet Pichard, Anaïs ^a   Mallet, Vincent ^a   Pol, Stanislas ^a  

^a APHP ^*  (France)

Author keywords

fatty liver disease; human immunodeficiency virus; metabolic syndrome; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; ALPHA INTERFERON; ALPHA TOCOPHEROL; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIRETROVIRUS AGENT; CYTOKERATIN 18; DIDANOSINE; EMTRICITABINE; FIBRIC ACID DERIVATIVE; GLITAZONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAMIVUDINE; LEPTIN; LOSARTAN; METFORMIN; NIVOCASAN; PEGINTERFERON ALPHA; PENTOXIFYLLINE; PIOGLITAZONE; PLACEBO; PROTEINASE INHIBITOR; RESISTIN; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSIGLITAZONE; STAVUDINE; TENOFOVIR; TUMOR NECROSIS FACTOR ALPHA;

ALCOHOL CONSUMPTION; ALCOHOLISM; APOPTOSIS; BODY MASS; CARDIOVASCULAR DISEASE; CD4 LYMPHOCYTE COUNT; COGNITIVE THERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENDOPLASMIC RETICULUM STRESS; EXERCISE; FOOD INTAKE; GENOTYPE; GLUCOSE METABOLISM; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; HYPOADIPONECTINEMIA; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIFESTYLE MODIFICATION; LIPID STORAGE; LIPODYSTROPHY; LIPOGENESIS; LIVER BIOPSY; LIVER CELL; LIVER FIBROSIS; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIDE EFFECT; STELLATE CELL; VIRUS LOAD; WEIGHT GAIN; WEIGHT REDUCTION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COINFECTION; FATTY LIVER; HEPACIVIRUS; HEPATITIS C; HIV; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; LIVER CIRRHOSIS; METABOLIC SYNDROME X; PREVALENCE;

EID: 84863209725     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0032-1316471     Document Type: Conference Paper

References (125)

1. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology: 2003; 37 5 1202 1219
2. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc: 1980; 55 7 434 438
3. Diehl AM. Nonalcoholic steatohepatitis. Semin Liver Dis: 1999; 19 2 221 229
4. Angulo P. Long-term mortality in nonalcoholic fatty liver disease: is liver histology of any prognostic significance? Hepatology: 2010; 51 2 373 375
5. Caldwell SH, Crespo DM. The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. J Hepatol: 2004; 40 4 578 584
6. Hui JM, Kench JG, Chitturi S., et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology: 2003; 38 2 420 427
7. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology: 2010; 51 5 1820 1832
8. Joint UN Programme on HIV/AIDS 2006 Report on the global AIDS epidemic: a UNAIDS 10th anniversary special edition. Executive summary. Available at: http://data.unaids.org/pub/ GlobalReport/2006/2006-gr-executivesummary-en.pdf. Accessed February 9, 2010
9. Mocroft A, Brettle R, Kirk O., et al. EuroSIDA study group Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS: 2002; 16 12 1663 1671
10. Weber R, Sabin CA, Friis-Moller N., et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med: 2006; 166 15 1632 1641
11. Salmon-Ceron D, Lewden C, Morlat P., et al. Mortality 2000 study group Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol: 2005; 42 6 799 805
12. Joshi D, O'Grady J, Dieterich D, Gazzard B, Agarwal K. Increasing burden of liver disease in patients with HIV infection. Lancet: 2011; 377 9772 1198 1209
13. Hu B, French SW. 2,3-Dideoxyinosine-induced Mallory bodies in patients with HIV. Am J Clin Pathol: 1997; 108 3 280 283
14. Coglan ME, Sommadossi JP, Jhala NC, Many WJ, Saag MS, Johnson VA. Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases. Clin Infect Dis: 2001; 33 11 1914 1921
15. Duong Van Huyen JP, Landau A, Piketty C., et al. Toxic effects of nucleoside reverse transcriptase inhibitors on the liver. Value of electron microscopy analysis for the diagnosis of mitochondrial cytopathy. Am J Clin Pathol: 2003; 119 4 546 555
16. Day CP, James OF. Steatohepatitis: a tale of two "hitso"? Gastroenterology: 1998; 114 4 842 845
17. Lavoie JM, Gauthier MS. Regulation of fat metabolism in the liver: link to non-alcoholic hepatic steatosis and impact of physical exercise. Cell Mol Life Sci: 2006; 63 12 1393 1409
18. Tessari P, Coracina A, Cosma A, Tiengo A. Hepatic lipid metabolism and non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis: 2009; 19 4 291 302
19. Parola M, Marra F. Adipokines and redox signaling: impact on fatty liver disease. Antioxid Redox Signal: 2011; 15 2 461 483
20. Larter CZ, Chitturi S, Heydet D, Farrell GC. A fresh look at NASH pathogenesis. Part 1: the metabolic movers. J Gastroenterol Hepatol: 2010; 25 4 672 690
21. Polyzos SA, Kountouras J, Zavos C. Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. Curr Mol Med: 2009; 9 3 299 314
22. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-α or adiponectin? Hepatology: 2004; 40 1 46 54
23. Sanyal AJ, Campbell-Sargent C, Mirshahi F., et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology: 2001; 120 5 1183 1192
24. Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis: 2001; 21 1 27 41
25. Seki S, Kitada T, Yamada T, Sakaguchi H, Nakatani K, Wakasa K. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J Hepatol: 2002; 37 1 56 62
26. Marchesini G, Marzocchi R, Agostini F, Bugianesi E. Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol: 2005; 16 4 421 427
27. Feldstein AE, Werneburg NW, Li Z, Bronk SF, Gores GJ. Bax inhibition protects against free fatty acid-induced lysosomal permeabilization. Am J Physiol Gastrointest Liver Physiol: 2006; 290 6 G1339 G1346
28. Wei Y, Wang D, Topczewski F, Pagliassotti MJ. Saturated fatty acids induce endoplasmic reticulum stress and apoptosis independently of ceramide in liver cells. Am J Physiol Endocrinol Metab: 2006; 291 2 E275 E281
29. Pessayre D, Fromenty B. NASH: a mitochondrial disease. J Hepatol: 2005; 42 6 928 940
30. Marra F, Bertolani C. Adipokines in liver diseases. Hepatology: 2009; 50 3 957 969
31. Marra F. Leptin and liver tissue repair: do rodent models provide the answers? J Hepatol: 2007; 46 1 12 18
32. Aleffi S, Petrai I, Bertolani C., et al. Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. Hepatology: 2005; 42 6 1339 1348
33. Jiang JX, Mikami K, Shah VH, Torok NJ. Leptin induces phagocytosis of apoptotic bodies by hepatic stellate cells via a Rho guanosine triphosphatase-dependent mechanism. Hepatology: 2008; 48 5 1497 1505
34. Iwai M, Horiuchi M. Role of renin-angiotensin system in adipose tissue dysfunction. Hypertens Res: 2009; 32 6 425 427
35. Moreno M, Bataller R. Cytokines and renin-angiotensin system signaling in hepatic fibrosis. Clin Liver Dis: 2008; 12 4 825 852, ix
36. Kohlstedt K, Gershome C, Trouvain C, Hofmann WK, Fichtlscherer S, Fleming I. Angiotensin-converting enzyme (ACE) inhibitors modulate cellular retinol-binding protein 1 and adiponectin expression in adipocytes via the ACE-dependent signaling cascade. Mol Pharmacol: 2009; 75 3 685 692
37. Crum-Cianflone N, Dilay A, Collins G., et al. Nonalcoholic fatty liver disease among HIV-infected persons. J Acquir Immune Defic Syndr: 2009; 50 5 464 473
38. Guaraldi G, Squillace N, Stentarelli C., et al. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. Clin Infect Dis: 2008; 47 2 250 257
39. Mohammed SS, Aghdassi E, Salit IE., et al. HIV-positive patients with nonalcoholic fatty liver disease have a lower body mass index and are more physically active than HIV-negative patients. J Acquir Immune Defic Syndr: 2007; 45 4 432 438
40. Ingiliz P, Valantin MA, Duvivier C., et al. Liver damage underlying unexplained transaminases elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy. Hepatology: 2009; 49 2 436 442
41. Marks K, Petrovic L, Talal A., et al. Histological findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIV and hepatitis C virus. J Infect Dis: 2005; 192 11 1943 1949
42. Laguno M, Milinkovic A, de Lazzari E., et al. Incidence and risk factors for mitochondrial toxicity in treated HIV/HCV-coinfected patients. Antivir Ther: 2005; 10 3 423 429
43. Piroth L. Liver steatosis in HIV-infected patients. AIDS Rev: 2005; 7 4 197 209
44. Hu KQ, Kyulo NL, Esrailian E., et al. Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a retrospective study on a large cohort of patients in the United States. J Hepatol: 2004; 40 1 147 154
45. Monto A, Alonzo J, Watson JJ, Grunfeld C, Wright TL. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology: 2002; 36 3 729 736
46. Browning JD, Szczepaniak LS, Dobbins R., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology: 2004; 40 6 1387 1395
47. Rubbia-Brandt L, Quadri R, Abid K., et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol: 2000; 33 1 106 115
48. Bani-Sadr F, Carrat F, Bedossa P., et al. Hepatic steatosis in HIV-HCV coinfected patients: analysis of risk factors. AIDS: 2006; 20 4 525 531
49. Castéra L, Loko MA, Le Bail B., et al. Hepatic steatosis in HIV-HCV coinfected patients in France: comparison with HCV-monoinfected patients matched for body mass index and HCV genotype. Aliment Pharmacol Ther: 2007; 26 11-12 1489 1498
50. McGovern BH, Ditelberg JS, Taylor LE., et al. Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infections in HIV-seropositive patients. Clin Infect Dis: 2006; 43 3 365 372
51. Neau D, Winnock M, Castéra L., et al. Prevalence of and factors associated with hepatic steatosis in patients coinfected with hepatitis C virus and HIV: Agence Nationale pour la Recherche contre le SIDA et les hépatites virales CO3 Aquitaine Cohort. J Acquir Immune Defic Syndr: 2007; 45 2 168 173
52. Rodríguez-Torres M, Govindarajan S, Solá R., et al. Hepatic steatosis in HIV/HCV co-infected patients: correlates, efficacy and outcomes of anti-HCV therapy: a paired liver biopsy study. J Hepatol: 2008; 48 5 756 764
53. Sterling RK, Contos MJ, Smith PG., et al. Steatohepatitis: risk factors and impact on disease severity in human immunodeficiency virus/hepatitis C virus coinfection. Hepatology: 2008; 47 4 1118 1127
54. Sulkowski MS, Mehta SH, Torbenson M., et al. Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS: 2005; 19 6 585 592
55. Kim AY, Chung RT. Coinfection with HIV-1 and HCVa one-two punch. Gastroenterology: 2009; 137 3 795 814
56. Gaslightwala I, Bini EJ. Impact of human immunodeficiency virus infection on the prevalence and severity of steatosis in patients with chronic hepatitis C virus infection. J Hepatol: 2006; 44 6 1026 1032
57. Machado MV, Oliveira AG, Cortez-Pinto H. Hepatic steatosis in patients coinfected with human immunodeficiency virus/hepatitis C virus: a meta-analysis of the risk factors. Hepatology: 2010; 52 3 71 78
58. Keithley JK, Duloy AM, Swanson B, Zeller JM. HIV infection and obesity: a review of the evidence. J Assoc Nurses AIDS Care: 2009; 20 4 260 274
59. Amorosa V, Synnestvedt M, Gross R., et al. A tale of 2 epidemics: the intersection between obesity and HIV infection in Philadelphia. J Acquir Immune Defic Syndr: 2005; 39 5 557 561
60. Lapadula G, Torti C, Paraninfo G., et al. EPOKa-A Study Group of the MASTER Cohort. Influence of hepatitis C genotypes on lipid levels in HIV-positive patients during highly active antiretroviral therapy. Antivir Ther: 2006; 11 4 521 527
61. Serfaty L, Andreani T, Giral P, Carbonell N, Chazouillères O, Poupon R. Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol: 2001; 34 3 428 434
62. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology: 2005; 42 1 44 52
63. Angulo P. GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther: 2007; 25 8 883 889
64. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology: 1990; 12 5 1106 1110
65. Moyle G, Carr A. HIV-associated lipodystrophy, metabolic complications, and antiretroviral toxicities. HIV Clin Trials: 2002; 3 1 89 98
66. Worm SW, Friis-Moller N, Bruyand M., et al. D:A:D study group High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. AIDS: 2010; 24 3 427 435
67. Monto A, Dove LM, Bostrom A, Kakar S, Tien PC, Wright TL. Hepatic steatosis in HIV/hepatitis C coinfection: prevalence and significance compared with hepatitis C monoinfection. Hepatology: 2005; 42 2 310 316
68. Sulkowski M, Mehta S, Montes de Occa R, Moore R, Thomas D. Estimated prevalence of significant liver disease among 4,052 HIV-infected adults with and without chronic hepatitis B and C. Paper presented at: 13th Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver, CO
69. DallaPiazza M, Amorosa VK, Localio R, Kostman JR, Lo Re V III. Prevalence and risk factors for significant liver fibrosis among HIV-monoinfected patients. BMC Infect Dis: 2010; 10 116
70. Castellares C, Barreiro P, Martín-Carbonero L., et al. Liver cirrhosis in HIV-infected patients: prevalence, aetiology and clinical outcome. J Viral Hepat: 2008; 15 3 165 172
71. Poynard T, Lebray P, Ingiliz P., et al. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest). BMC Gastroenterol: 2010; 10 40
72. Paradis V, Perlemuter G, Bonvoust F., et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology: 2001; 34 4 Pt 1 738 744
73. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology: 1999; 30 6 1356 1362
74. Jaskiewicz K, Rzepko R, Sledzinski Z. Fibrogenesis in fatty liver associated with obesity and diabetes mellitus type 2. Dig Dis Sci: 2008; 53 3 785 788
75. Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol: 2005; 42 1 132 138
76. Bhala N, Angulo P, van der Poorten D., et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology: 2011; 54 4 1208 1216
77. Woreta TA, Sutcliffe CG, Mehta SH., et al. Incidence and risk factors for steatosis progression in adults coinfected with HIV and hepatitis C virus. Gastroenterology: 2011; 140 3 809 817
78. Sterling RK, Wegelin JA, Smith PG., et al. Similar progression of fibrosis between HIV/HCV-infected and HCV-infected patients: analysis of paired liver biopsy samples. Clin Gastroenterol Hepatol: 2010; 8 12 1070 1076
79. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology: 1999; 116 6 1413 1419
80. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med: 2001; 344 7 495 500
81. Qayyum A, Chen DM, Breiman RS., et al. Evaluation of diffuse liver steatosis by ultrasound, computed tomography, and magnetic resonance imaging: which modality is best? Clin Imaging: 2009; 33 2 110 115
82. Schwenzer NF, Springer F, Schraml C, Stefan N, Machann J, Schick F. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol: 2009; 51 3 433 445
83. Lee SW, Park SH, Kim KW., et al. Unenhanced CT for assessment of macrovesicular hepatic steatosis in living liver donors: comparison of visual grading with liver attenuation index. Radiology: 2007; 244 2 479 485
84. Limanond P, Raman SS, Lassman C., et al. Macrovesicular hepatic steatosis in living related liver donors: correlation between CT and histologic findings. Radiology: 2004; 230 1 276 280
85. Park SH, Kim PN, Kim KW., et al. Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment. Radiology: 2006; 239 1 105 112
86. Liu ZJ, Gong JP, Yan LN. Quantitative estimation of the degree of hepatic macrovesicular steatosis in a disease-free population: a single-center experience in mainland China. Liver Transpl: 2009; 15 11 1605 1612
87. Shores NJ, Link K, Fernandez A., et al. Non-contrasted computed tomography for the accurate measurement of liver steatosis in obese patients. Dig Dis Sci: 2011; 56 7 2145 2151
88. Hadigan C, Liebau J, Andersen R, Holalkere NS, Sahani DV. Magnetic resonance spectroscopy of hepatic lipid content and associated risk factors in HIV infection. J Acquir Immune Defic Syndr: 2007; 46 3 312 317
89. Ghotb A, Noworolski SM, Madden E., et al. Adipose tissue and metabolic factors associated with steatosis in HIV/HCV coinfection: histology versus magnetic resonance spectroscopy. J Acquir Immune Defic Syndr: 2010; 55 2 228 231
90. Poynard T, Ratziu V, Charlotte F., et al. LIDO Study Group; CYTOL study group Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol: 2006; 6 34
91. Zein CO, Edmison JM, Schluchter M, Feldstein AE, Zein NN, McCullough AJ. A NASH predictive index (NPI) for use in patients with non-alcoholic fatty liver disease. Hepatology: 2007; 46 Suppl 1 747A
92. Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology: 2009; 50 4 1072 1078
93. Musso G, Gambino R, Durazzo M, Cassader M. Noninvasive assessment of liver disease severity with liver fat score and CK-18 in NAFLD: Prognostic value of liver fat equation goes beyond hepatic fat estimation. Hepatology: 2010; 51 2 715 717
94. Ratziu V, Massard J, Charlotte F., et al. LIDO Study Group; CYTOL study group Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol: 2006; 6 6
95. Angulo P, Hui J, Marchesini G., et al. The NAFLD fibrosis score: a non-invasive system that identifies liver fibrosis in patients with NAFLD. Hepatology: 2007; 45 849 854
96. Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut: 2008; 57 10 1441 1447
97. Guha I, Parkes J, Roderick P., et al. Noninvasive markers of fibrosis in non alcoholic fatty liver disease: validating the European liver fibrosis panel and exploring simple markers. Hepatology: 2009; 47 455 460
98. Calès P, Lainé F, Boursier J., et al. Comparison of blood tests for liver fibrosis specific or not to NAFLD. J Hepatol: 2009; 50 1 165 173
99. Kelleher T, MacFarlane C, de Ledinghen V., et al. Risk factors and hepatic elastography (FibroScan) in the prediction of hepatic fibrosis in non-alcoholic steatohepatitis. Gastroenterology: 2006; 130 A736
100. Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med: 2011; 43 8 617 649
101. Castéra L, Foucher J, Bernard PH., et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology: 2010; 51 3 828 835
102. 2 J Hepatol: 2009; 50 Suppl 1 359
103. Joka D, Wahl K, Moeller S., et al. Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis. Hepatology: 2012; 55 2 455 464
104. Zelber-Sagi S, Ratziu V, Oren R. Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence. World J Gastroenterol: 2011; 17 29 3377 3389
105. Neuschwander-Tetri BA. Lifestyle modification as the primary treatment of NASH. Clin Liver Dis: 2009; 13 4 649 665
106. Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes: 2005; 54 3 603 608
107. Tiikkainen M, Bergholm R, Vehkavaara S., et al. Effects of identical weight loss on body composition and features of insulin resistance in obese women with high and low liver fat content. Diabetes: 2003; 52 3 701 707
108. Suzuki A, Lindor K, St Saver J., et al. Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. J Hepatol: 2005; 43 6 1060 1066
109. Promrat K, Kleiner DE, Niemeier HM., et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology: 2010; 51 1 121 129
110. Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology: 2010; 52 1 79 104
111. Parker HM, Johnson NA, Burdon CA, Cohn JS, O'Connor HT, George J. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol: 2012; 56 4 944 951
112. St George A, Bauman A, Johnston A, Farrell G, Chey T, George J. Independent effects of physical activity in patients with nonalcoholic fatty liver disease. Hepatology: 2009; 50 1 68 76
113. Moscatiello S, Marzocchi R, Villanova N, Bugianesi E, Marchesini G. Which treatment for nonalcoholic fatty liver disease? Mini Rev Med Chem: 2008; 8 8 767 775
114. Lutchman G, Modi A, Kleiner DE., et al. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology: 2007; 46 2 424 429
115. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology: 2009; 49 1 306 317
116. Lavine JE, Schwimmer JB, Van Natta ML., et al. Nonalcoholic Steatohepatitis Clinical Research Network. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA: 2011; 305 16 1659 1668
117. Sanyal AJ, Chalasani N, Kowdley KV., et al. NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med: 2010; 362 18 1675 1685
118. Lindor KD, Kowdley KV, Heathcote EJ., et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology: 2004; 39 3 770 778
119. Yokohama S, Yoneda M, Haneda M., et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology: 2004; 40 5 1222 1225
120. Torres DM, Jones FJ, Shaw JC, Williams CD, Ward JA, Harrison SA. Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open-label trial. Hepatology: 2011; 54 5 1631 1639
121. Ratziu V, Sheikh MY, Sanyal AJ., et al. A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis. Hepatology: 2012; 55 2 419 428
122. Satapathy SK, Sakhuja P, Malhotra V, Sharma BC, Sarin SK. Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol: 2007; 22 5 634 638
123. Zein C, Yerian L, Cogate P., et al. Pentoxyfylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology 54 5 1610 1619
124. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Available at: http://www.aidsinfo.nih.gov/ContentFiles.AdultandAdolescentGL.pdf. Accessed March 1, 2012
125. Gallant JE, Staszewski S, Pozniak AL., et al. 903 Study Group Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA: 2004; 292 2 191 201